ProCE Banner Activity

Antibody–Drug Conjugates and the Role of TROP-2 in NSCLC

Slideset

Download this slideset from a live symposium at ELCC 2024 for an expert overview of TROP-2 ADCs in advanced NSCLC, including the need for new therapies in relapsed disease, what ADCs are and how they work, and TROP-2 as a therapeutic target for these new agents.

Released: March 19, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.